MedWatch

Analyst foresaw Ambu flop: "I simply didn’t trust the information I got from the company"

Especially one analyst remained skeptical towards Ambu’s praise for its growth hope, the colonoscope SC210. “It’s okay to be optimistic but you still have to give the market correct information,” says the Carnegie analyst who was not particularly surprised by Ambu’s recent adjustment of the financial outlook and following share price decline.

Niels Granholm-Leth, chefaktieanalytiker, Carnegie
Photo: PR, Carnegie

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles